Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linvoseltamab + isatuximab
- Development stage
- Phase 1
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Linvoseltamab + isatuximab is an investigational combination therapy for multiple myeloma, studied primarily in relapsed/refractory patients. **Linvoseltamab** is a bispecific monoclonal antibody that binds both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T-cells, redirecting cytotoxic T cells to target and kill BCMA-expressing tumor cells. **Isatuximab** is an anti-CD38 IgG1 monoclonal antibody that directly binds the CD38 receptor on myeloma cells, inducing cell death through immune effector mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis, as well as modulation of enzymatic activity of CD38 and restoration of antitumor immune responses. The combination is under clinical evaluation to determine safety, dosing, and anti-myeloma activity.[5][7][4][2]
02
Targets
BCMA (B-cell maturation antigen)CD38 (Cluster of Differentiation 38)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on linvoseltamab + isatuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linvoseltamab + isatuximab.